Effect observation of diterpene ginkgolides meglumine injection in improvement of neurological function in patients with acute cerebral infarction
-
摘要: 目的 探讨银杏二萜内酯葡胺(DGMI)对急性脑梗死患者血浆Ⅰ型纤溶酶原激活物抑制因子(PAI-1)水平及神经功能的影响。 方法 选择急性脑梗死患者80例,随机分为DGMI组与对照组,每组40例。DGMI组给予静脉滴注DGMI 25 mg/d, 连续治疗14 d; 对照组给予无DGMI的基础治疗。比较2组治疗前、治疗14 d后神经功能缺损程度、血栓弹力图(TEG)参数、血浆PAI-1水平。 结果 治疗14 d后, 2组美国国立卫生研究院卒中量表(NIHSS)评分与Barthel指数均优于治疗前,且DGMI组NIHSS评分与Barthel指数均优于对照组,差异有统计学意义(P<0.05)。治疗14 d后, DGMI组TEG中R值与K值均较治疗前升高, Angel角与MA值均较治疗前降低,差异有统计学意义(P<0.05); 对照组治疗后MA值与治疗前比较,差异有统计学意义(P<0.05); DGMI组R值与K值均高于对照组, Angel角与MA值均低于对照组,差异有统计学意义(P<0.05)。治疗后, DGMI组血浆PAI-1水平降低,且低于对照组,差异有统计学意义(P<0.05)。 结论 DGMI可能通过调控血浆PAI-1的水平来影响凝血与纤维溶解系统的活性,进而改善患者的神经功能缺损症状。
-
关键词:
- 银杏二萜内酯葡胺 /
- 血浆Ⅰ型纤溶酶原激活物抑制因子 /
- 急性脑梗死 /
- 血栓弹力图 /
- 神经功能缺损
Abstract: Objective To explore the effect of diterpene ginkgolides meglumine injection(DGMI)on the level of plasma type Ⅰ plasminogen activator inhibitor(PAI-1)and neurological function in patients with acute cerebral infarction. Methods Eighty patients with acute cerebral infarction were selected and randomly divided into DGMI group and control group, with 40 cases in each group. The DGMI group was treated with intravenous infusion of DGMI for 25 mg per day for 14 days, while the control group was given basic treatment without DGMI. The degree of neurological deficit, parameters of thromboelastography(TEG)and plasma PAI-1 level were compared between the two groups before and after 14 days of treatment. Results After 14 days of treatment, the National Institutes of Health Stroke Scale(NIHSS)score and Barthel index in both groups were significantly better than those before treatment, and the NIHSS score and Barthel index of the DGMI group were significantly better than those of the control group(P<0.05). After 14 days of treatment, the R value and K value of TEG in the DGMI group were significantly higher than those before treatment, while degree of Angel and MA value were significantly lower than those before treatment(P<0.05). After treatment, the MA value in the control group showed significant difference when compared to treatment before(P<0.05). The R value and K value of the DGMI group were significantly higher than those of the control - group, while the degree of Angel and MA value were significantly lower than those of the control group (P<0.05). After treatment, the plasma PAI-1 level in the DGMI group was significantly lower than that treatment before and the control group(P<0.05). Conclusion DGMI may affect the activity of coagulation and fibrinolysis system by regulating the plasma level of PAI-1, thereby improving the symptoms of neurological deficit in patients. -
-
LIU S, WANG K H, DUAN X J, et al. Efficacy of Danshen Class Injection in the Treatment of Acute Cerebral Infarction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials[J]. Evid Based Complement Alternat Med, 2019, 2019(1): 1-12.
JIA C, WEI C, HU M, et al. Correlation between antiplatelet therapy in secondary prevention of acute cerebral infarction and cerebral microbleeds: a susceptibility-weighted imaging(SWI)study[J]. J Xray Sci Technol, 2018, 26(4): 623-633.
LIU Y, WU X, YU Z. Ginkgo leaf extract and dipyridamole injection as adjuvant treatment for acute cerebral infarction: Protocol for systemic review and meta-analysis of randomized controlled trials[J]. Medicine(Baltimore), 2019, 98(8): e14643.
YAMAMOTO K, TAKESHITA K, SAITO H. Plasminogen activator inhibitor-1 in aging[J]. Semin Thromb Hemost, 2014, 40(6): 652-659.
BONTEKOE I J, VAN DER MEER P F, KORTE D. Thromboelastography as a tool to evaluate blood of healthy volunteers and blood component quality: a review[J]. Vox Sang, 2019, 114(7): 643-657.
Wang YJ, ZHANG J, SHENG J F, et al. Immunoreactive Cells After Cerebral Ischemia[J]. Front Immunol, 2019, 10: 2781-2792.
DEMAERSCHALK B M, KLEINDORFER D O, ADEOYE O M, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American heart association/American stroke association[J]. Stroke, 2016, 47(2): 581-641.
MACLENNAN K. The CNS effects of Ginkgo biloba extracts and ginkgolide B[J]. Prog Neurobiol, 2002, 67(3): 235-257.
LOU C, LU H, MA Z, et al. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway[J]. Biomed Pharmacother, 2019, 109: 563-572.
HSU C L, WU Y L, TANG G J, et al. Ginkgo biloba extract confers protection from cigarette smoke extract-induced apoptosis in human lung endothelial cells: Role of heme oxygenase-1[J]. Pulm Pharmacol Ther, 2009, 22(4): 286-296.
张鹏飞, 廖丽君, 谭玉萍. 银杏叶提取物治疗慢性阻塞性肺疾病作用机制的研究进展[J]. 中国全科医学, 2017, 20(15): 1906-1910. ZHANG F, LUO J, ZHU X L. Ketamine ameliorates depressive-like behaviors by tPA-mediated conversion of proBDNF to mBDNF in the hippocampus of stressed rats[J]. Psychiatry Res, 2018, 269: 646-651.
-
期刊类型引用(10)
1. 王晶一，郑娅，史海燕. 银杏二萜内酯葡胺注射液联合调督舒筋手法对急性脑梗死患者ET-1、S100β及血液流变学的影响. 中国基层医药. 2024(11): 1693-1698 . 
百度学术
2. 朱珊珊，崔丽，徐军伟. 银杏二萜内酯葡胺联合阿加曲班在急性脑梗死中的应用效果. 河南医学研究. 2023(11): 2043-2047 . 百度学术
3. 卢长岭. 银杏二萜内酯葡胺在急性缺血性脑卒中患者中的应用. 实用中西医结合临床. 2023(18): 20-22+33 . 百度学术
4. 周承升，赵浚乐. 依达拉奉联合银杏二萜内酯治疗脑梗死后功能障碍的效果. 内蒙古中医药. 2022(03): 109-111 . 百度学术
5. 张怡. 双抗与银杏二萜内酯葡胺联合替罗非班治疗小分支脑动脉闭塞引发急性脑梗死的疗效对比. 当代临床医刊. 2022(03): 66-67 . 百度学术
6. 郭娟娟. 银杏二萜内酯葡胺与阿司匹林在急性脑梗死中的治疗效果及对BI、NIHSS、QOLISP评分的影响分析. 中外医疗. 2022(09): 14-18 . 百度学术
7. 李瑾，高晓红，王玉梅. 银杏二萜内酯葡胺对脑梗死合并多发性颅内动脉狭窄的影响. 中国社区医师. 2022(19): 55-57 . 百度学术
8. 周安. 阿加曲班联合银杏二萜内酯葡胺注射液治疗后循环脑梗死的效果. 医学理论与实践. 2022(20): 3464-3466 . 百度学术
9. 孙忠发，吴剑冰，尤东阳，孙强. 银杏二萜注射液对急性脑梗死溶栓患者认知功能与血液流变学的影响. 北方药学. 2022(11): 10-12 . 百度学术
10. 李贞，蒋磊，徐维平. 242例住院患者银杏二萜内酯葡胺注射液合理用药分析. 中国药业. 2021(14): 111-113 . 百度学术
其他类型引用(2)
计量
- 文章访问数: 314
- HTML全文浏览量: 87
- PDF下载量: 8
- 被引次数: 12
下载:
苏公网安备 32100302010246号